Gynae BT 2017

PORTEC-2 trial (2002-2006)

Stage I high-intermediate risk (n = 427)

• age > 60 and ≥50% invasion grd 1-2 or <50% invasion grd 3 • FIGO 1988 stage 2A • TAH-BSO without lymphadenectomy

pelvic radiotherapy

46 Gy / 23# / 5 wks

R

vaginal brachytherapy

21 Gy / 3# / 2 wks

2

Nout et al, Lancet 2010